Pampfer Serge Email & Phone Number

Belgium

LovalTech is a start-up company dedicated to developing nasal vaccines against infectious diseases. Nasal vaccine administration triggers a mucosal immune response that blocks contagiousness and prevents transmission, on top of the classical immune response activated by the intra-muscular route. The first vaccine candidate developed by Lovaltech is ready for entering phase I/IIa clinical trials in 2024.

MAEDIA srl combines activities in corporate management and in book publishing since 2010. Consulting activities include C-Level and Board-level duties in the life sciences industry while publishing activities comprise "in conversation with" interviews and other interactions with artists. In both endeavors, the focus of MAEDIA is on transversal value creation and community sharing.

EureKARE is an international investment company focused on the creation and expansion of companies active in either microbiome or synthetic biology in Europe. EureKARE has established two biotech studios, one in Paris and one in Brussels, to stimulate the emergence of new technologies and applications in these two markets, both of them being driven by impressive 25% annual growth rates. EureKARE also develops an AI-powered tool to identify the most promising scientists and institutions doing research in microbiome and synthetic biology in order to secure premium access to the best science and innovation Europe is producing in these fields. In terms of investment capacity, EureKARE has already raised around € 50 million to be engaged in both new startups and maturing companies in 2021-2022.

Liege, Liège, Be

WBC Ventures is the new iteration of our original company (Biotech Coaching SA). After 12 years operating as a successful incubator and seed investor for 60+ life science companies, we have transitioned to an accelerator and consulting business model in early 2019. Around our new core Market Access Accelerator Program and leveraging our long and proven experience in the life science (biotech, medtech, healthtech and agri-foodtech) sector, we have assembled a tight network of experts, mentors, financial and industrial partners and alumni to help scaling-up companies meet their global objectives and achieve maximal societal and commercial impact. WBC Ventures also offers screening and scouting services to investors looking for qualified investment proposals and to companies looking for acquisition or licensing opprotunities.

Liege, Liège, Be

WBC Incubator (Biotech Coaching SA) was launched by the Region of Wallonia in 2006 to stimulate the creation and expansion of life science spin-offs, start-ups and spin-outs in the French-speaking part of Belgium. Over the past years, WBC has contributed to the creation of 60 new companies whose innovative applications range from cell therapy to water bioremediation to neuromodulation devices. WBC also supports more mature companies during their industrial and commercial phases. WBC invests about 1.5 M€ in its portfolio companies every year and is currently a shareholder and board observer in several of them.

Antwerpen, Be

Peace of Meat is the first Cultivated Meat pure player to be launched in Belgium. Based on a unique strategy focusing on building premium development and manufacturing consortia around the world, Peace of Meat aims to deliver exceptional cultivated / clean / cultured / cell-based / lab-grown / in vitro / you-name-it / meat products to the food market.

Beta-Cell NV was created as a spin-off company to develop novel cell therapies for type I diabetes. Its first preclinical program involved the use of fetal pig pancreatic cells and their study for graft survival, functionality and safety in non-human primates. The company also diversified its product pipeline through the design and validation of an innovative screening platform that was proposed to the biopharmaceutical industry to identify new drug candidates for diabetes.

Arevia GmbH was created as a start-up company to discover and validate new biomarkers and potential drug targets for endometriosis. Its innovative screening platform led to the identification of several new genes and proteins that were functionally linked to the disease occurence and progression. Arevia GmbH was acquired by Schering (now Bayer Pharma) AG.

One of the research programs pursued in the Human Reproduction Research Unit of the University of Louvain School of Medecine was aimed at a better understanding of the cellular and molecular regulation of murine and human embryos during the preimplantation phase of pregnancy. This program led to major findings in the mechanisms of cellular apoptosis, stem cell differentiation and cytokine interactions as well as about the impact of maternal diabetes on early embryonic development.

Molecular Biology

Cellular Biology